Aramine® hydrogen tartrate (levo-1-[m-hydroxyphenyl]-2-amino-1-propanol d-hydrogen tartrate)1 is a new sympathomimetic amine designed for active, prolonged constriction of blood vessels. As a compound for nasal medication, it fulfills the requirements of being isotonic, slightly acid (pH 6.0), buffered, an effective vasoconstrictor without vasodilatory action, and without local or systemic toxicity.2
Controlled laboratory experiments revealed that aramine® has no deleterious effect (gross or microscopic) upon rabbit nasal mucosa or conjunctiva after 45 daily instillations of 0.5% aramine® solution. The ciliary activity of normal rabbit trachea is not affected by immersion in aramine® for one to two minutes. After two to four minutes, there may be mild inhibition of ciliary motility.3 Aramine® usually causes no increase in pulse rate or cardiac arrhythmias when given in less than maximal pressor doses, a characteristic of sympathomimetic amines with a metahydroxyl group on the aromatic
TAYLOR GW. CLINICAL EVALUATION OF ARAMINE,® A NEW SYMPATHOMIMETIC AMINE. AMA Arch Otolaryngol. 1952;56(2):213–214. doi:10.1001/archotol.1952.00710020232015
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: